Nasdaq biotech news
Capricor Gains 11% as FDA Pushes Deramiocel Decision to Nov
A three-month delay is not usually something a stock rallies on. Capricor Therapeutics gained 11% anyway. The company’s Duchenne muscular dystrophy therapy just got a longer FDA review instead of a decision, and investors treated the extra scrutiny as a sign the door stayed open rather than a rejection in slow motion. Capricor Gains 11%…
OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration
OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one. OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million OmniAb (Nasdaq:…
Faeth Therapeutics Jumps 18% as Cash Grows to $186 Million
Faeth Therapeutics and Veru posted double-digit stock gains on the same Monday, for reasons that had nothing to do with each other. Faeth used its quarterly numbers to show it is sitting on nine times the cash it had six months ago. Veru used its own earnings call to confirm a trial enrolled faster than…
Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Panel
Nine advisory committee members looked at the same trial data Capricor called a win and voted against it. The 9-3 result on July 29 didn’t kill Capricor’s Duchenne muscular dystrophy program, but it added a real question mark to a therapy the company insists already cleared its bar. INmune Bio spent the same stretch doing…
Capricor Plunges 67% on FDA Panel News Ahead of DMD Vote
Capricor Therapeutics lost roughly two-thirds of its market value on Monday. Not from a failed trial. From a document explaining what a panel might discuss on Wednesday. Curis and Autonomix Medical had smaller, quieter reactions of their own to their own news this week, one up, one down, each worth understanding on its own terms.…
CareDx Jumps on Medicare Win, OKYO Pharma Funds Phase 3 Trial
A federal coverage policy that took a year to finalize added more than $200 million to CareDx’s market value in a single trading session. Nothing about the underlying science changed. The paperwork did. Two much smaller names had quieter weeks of their own: one locked in the cash to finish its pivotal trial, the other…
